18-Aug-2026
Recursion Pharmaceuticals (RXRX) Gets a Hold from Morgan Stanley
TipRanks (Mon, 17-Aug 8:56 AM ET)
Globe Newswire (Wed, 5-Aug 6:30 AM ET)
Recursion to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 4-Aug 8:00 AM ET)
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Globe Newswire (Fri, 31-Jul 4:30 PM ET)
Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
Globe Newswire (Wed, 29-Jul 8:30 AM ET)
PRNewswire (Wed, 1-Jul 9:01 AM ET)
PRNewswire (Tue, 30-Jun 9:00 AM ET)
The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It
PRNewswire (Tue, 16-Jun 8:45 AM ET)
Globe Newswire (Tue, 19-May 12:07 PM ET)
Market Chameleon (Mon, 8-Dec 2:58 AM ET)
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
Recursion Pharmaceuticals - Class A trades on the NASDAQ stock market under the symbol RXRX.
As of August 18, 2026, RXRX stock price declined to $3.09 with 15,282,412 million shares trading.
RXRX has a beta of 2.70, meaning it tends to be more sensitive to market movements. RXRX has a correlation of 0.30 to the broad based SPY ETF.
RXRX has a market cap of $1.66 billion. This is considered a Small Cap stock.
Last quarter Recursion Pharmaceuticals - Class A reported $8 million in Revenue and -$.25 earnings per share. This fell short of revenue expectation by $-5 million and missed earnings estimates by -$.01.
In the last 3 years, RXRX traded as high as $15.74 and as low as $2.77.
The top ETF exchange traded funds that RXRX belongs to (by Net Assets): XBI, ARKK, ARKE, VTI, ARKG.
RXRX has underperformed the market in the last year with a price return of -46.4% while the SPY ETF gained +20.4%. However, in the short term, RXRX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +5.5% vs +4.1% return in SPY. But in the last 2 weeks, RXRX shares have been beat by the market, returning -2.8% compared to an SPY return of +1.3%.
RXRX support price is $3.00 and resistance is $3.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RXRX shares will trade within this expected range on the day.
